Junjiro Rikitake, Kenji Ashida, Ayako Nagayama, Yukihiro Inoguchi, Nao Hasuzawa, Masamichi Koganemaru, Tetsuya Hamada, Kanoko Moritaka, Mutsuyuki Demiya, Tomoki Sako, Jun Akiba, Koji Hiraoka, Masatoshi Nomura
BACKGROUND Tumor-induced osteomalacia (TIO) is a paraneoplastic syndrome caused by aberrant fibroblast growth factor-23 (FGF-23)-producing tumors. Early surgical resection is the optimal strategy for preventing TIO progression. Thus, tumor localization is a priority for successful treatment. A simple and safe examination method to identify functional endocrine tumors is essential to achieve better outcomes in patients with TIO. CASE REPORT A 64-year-old Japanese man with recurrent fractures, hypophosphatemia, and elevated alkaline phosphatase and FGF-23 levels (109 pg/mL) was admitted to our university hospital and was diagnosed with FGF23-related hypophosphatemic osteomalacia...
April 13, 2024: American Journal of Case Reports